Contact us   |  



In the frame of a multidisciplinary consortium that integrates clinical scientists, pediatricians, health and humanity experts, statisticians and technical experts from partner organizations, the project "Master framework and pragmatic clinical trial for relapse or refractory acute myeloid leukemia (IMPACT- AML)"  (GA 101104421) has been initiated.

IMPACT-AML, represents a model of high-impact disease, in which no standard of care exists, and where there is an urgent need for new evidence on possible therapies; AML offers the setting in which methodological innovation will combine powerful instruments of clinical trials with personalized medicine through academic efforts. The project proposes are to create an inclusive master framework for relapsed or refractory acute myeloid leukemia (STREAM) to include patients with R/R AML across Europe proficiently acquire an unselected population for clinical trials and monitor outcomes including neglected cohorts.

Acute Myeloid Leukemia (AML) is a group of neoplasms arising from precursor cells committed to the myeloid cell-line differentiation. All of them are characterized by clonal expansion of myeloid blasts.

STREAM will be an open platform for the registration of R/R AML patients. It will be developed under ENROL. Inside ENROL, STREAM will collect demographics, diagnosis methods, genetic data, main clinical manifestations, treatments, and survival; Data will be collected and harmonized according to predefined core sets and ontologies at the EU level by enabling the connection, upgrading, and building of EU patients registries in line with EU data protection and interoperability standards and has within is major objectives to promote research allowing the identification of patient cohorts to ensure enrolment and patient selection for the RPCT, facilitate the development of collaborative projects on basic and clinical research on R/R AML. STREAM will allow data gathering open to any EU data provider willing to contribute, including healthcare providers (ERN-EuroBloodNet members / Other EU healthcare providers) and European/national/regional registries.

The consortium currently includes 17 Institutions and is led by Dr. Giovanni Martinelli from IRCSS Istituto Romagnolo per lo Studio e la Cura dei Tumori "Dino Amadori", Italy. Among the other institutions there are 4 ERN-EuroBloodNet Members*:

Euro Blood Net